Aromatase inhibitors raise fracture risk

Postmenopausal women given aromatase inhibitors for breast cancer are more likely to develop fractures and low bone density than their counterparts treated with other cancer agents, a study finds.

Fracture rates were 50% higher among women who received aromatase inhibitors than those given tamoxifen or placebo, according to the review, which included data on more than 32,000 postmenopausal women with early-stage breast cancer.

There was also a trend towards lower bone density in